Lundbeck appoints Dr. Rupert Sandbrink as Head of Clinical Development
H. Lundbeck A/S (Lundbeck) Dr. Sandbrink will join Lundbeck on 1 January 2022 as Senior Vice President, Head of Clinical Development.
Dr. Sandbrink will play a vital role in advancing Lundbeck’s clinical pipeline towards providing transformative medicines for people living with niche and rare brain diseases.
“I am looking forward to Rupert joining our R&D team. He brings strong leadership and broad expertise in all stages of Clinical Development. His impressive track record in successful drug development, in particular his experience in neuroimmunology and rare diseases, matched with our strong neuroscience dedicated clinical development organization, will enable us to further advance on our prioritized biology areas and to deliver innovative and life-changing therapies,” says Johan Luthman, Executive Vice President for Research & Development.
Dr. Sandbrink is a highly accomplished Clinical Development leader in both larger pharmaceutical companies as well as small biotechnology entities. He brings more than 20 years of experience spanning all stages of clinical development, from First-in-Human and translational/experimental medicine studies to pivotal trials, regulatory submissions and product launches, including Medical Affairs, Regulatory Affairs and Pharmacovigilance.
Dr. Sandbrink grew up in Germany and received his MD from the University of Heidelberg. He also has a PhD in the Alzheimer’s disease research field. He is the author of more than 80 scientific publications.
“Lundbeck is a recognized premier neuroscience company with a long history and reputation for innovation. I’m thrilled to have the opportunity to be a part of Lundbeck’s R&D team and to continue the work to provide breakthrough treatments for people with brain diseases,” says Dr. Sandbrink.
|Palle Holm Olesen||Thomas Mikkel Mortensen|
|Vice President, Investor Relations||Media Relations Lead, Corp. Communication|
|+45 30 83 24 26||+45 30 83 30 24|
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.
Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Every day, we strive for improved treatment and a better life for people living with brain disease.
We have approximately 5,600 employees in more than 50 countries, and our products are available in more than 100 countries. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Lundbeck generated revenue of DKK 17.7 billion in 2020 (EUR 2.4 billion; USD 2.7 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com, and connect with us on Twitter at @Lundbeck and via LinkedIn. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311